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Abstract: The field of Philadelphia-chromosome-negative chronic myeloproliferative
neoplasms (MPNs) has recently witnessed tremendous advances in the basic knowledge of
disease pathophysiology that followed the identification of mutations in JAK2 and MPL.
These discoveries led to a revision of the criteria employed for diagnosis by the World Health
Organization. The prognostic role of the JAK2 V617F mutation and of its allelic burden has been
the objective of intensive research using a variety of cellular and animal models as well as in
large series of patients. While a definitive position cannot yet been taken on all of the issues,
there is a consensus that the presence of higher V617F allele burden, that is on the basis of a
stronger activation of intracellular signalling pathways, is associated with the clinical pheno-
type of polycythemia vera and with defined haematological and clinical markers indicative of a
more aggressive phenotype. On the other hand, a low allele burden in myelofibrosis is asso-
ciated with reduced survival. Finally, a significant reduction of JAK2 V617F allele burden has
been demonstrated in patients treated with interferon, while the effects of novel JAK1 and
JAK2 inhibitors have not yet been fully ascertained.
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Introduction
The Philadelphia-chromosome-negative chronic
myeloproliferative neoplasms (MPNs) include
polycythemia vera (PV), essential thrombocythe-
mia (ET) and primary myelofibrosis (PMF)
[Vannucchi et al. 2009b]. PV and ET are rela-
tively indolent disorders which result in a
modest reduction in survival, usually after the
first decade far from diagnosis; in contrast,
PMF has a more severe course with a median
survival of about 5 years, although some patients
experience survival longer than 10 years. The
course of PV and ET is marked by an excess of
arterial and venous thromboses, which represent
the principal cause of morbidity and mortality;
major haemorrhages, evolving into postpoly-
cythemic or postthrombocythemic myelofibrosis
(PPV/PET-MF; collectively known as ‘MPN-
associated myelofibrosis’ (MPN-MF) and
including all of the MPNs with bone marrow
fibrosis) [Mesa et al. 2010], and transformation
to acute myeloid leukaemia (AML) also contrib-
ute to reduced survival.
The molecular lesion(s) that form the basis of
MPNs remained unknown until 2005, when a
point mutation in exon 14 of Janus kinase
2 gene (JAK2V617F) was discovered in patients
with all three classic MPNs [Baxter et al. 2005;
James et al. 2005; Kralovics et al. 2005a; Levine
et al. 2005]. Further studies demonstrated that
the V617F allele is harboured by more than
95% of patients with PV and about 60% of
those with ET or PMF [Guglielmelli et al.
2009b; Tefferi et al. 2008, 2006, 2005; Barosi
et al. 2007; Vannucchi et al. 2007b; Antonioli
et al. 2005; Wolanskyj et al. 2005]. Additional
mutations in exon 12 of JAK2 were described
in a few patients with PV lacking the V617F
allele [Scott et al. 2007], while mutations at
codon 515 of MPL [Pikman et al. 2006] have
been described in 38% of patients with ET
and PMF [Vannucchi et al. 2008a; Beer et al.
2008; Guglielmelli et al. 2007; Pardanani et al.
2006]. These mutant alleles all result in a gain
of function due to constitutive activation of
tyrosine kinase-dependent cellular signalling
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pathways, particularly the JAKSTAT pathway
[Levine et al. 2007]. However, evidence of acti-
vation of the JAKSTAT pathway is also found in
patients who lack mutations in JAK2 or MPL,
pointing to still unknown mutations in other
genes linked to this pathway. One of these is
LNK, which encodes for a member of a family
of adaptor proteins involved in the negative
regulation of JAK/STAT signalling. Mutations
in LNK have recently been reported in patients
with JAK2-negative MPNs [Oh et al. 2010]
including subjects with erythrocytosis
[Lasho et al. 2010].
As a whole, this information has significantly
advanced our understanding of the mechanisms
that form the basis of MPNs, and has almost
immediately prompted a modification of the
diagnostic criteria redacted from the World
Health Organization (WHO) [Swerdlow et al.
2008; Tefferi et al. 2007]. Furthermore, by point-
ing out mutated kinases as a common mechanism
in MPNs, these molecular discoveries have
formed the basis for the development and clini-
cal exploitation of small inhibitors of JAK2,
with the hope of reproducing the successful his-
tory of the tyrosine kinase inhibitor imatinib
in chronic myelogenous leukaemia [Goldman
et al. 2009].
The puzzle of ‘one-mutation-different
diseases’
One major issue that emerged from the very first
studies is how a single mutation in JAK2 could
form the basis of at least three major clinical
phenotypes, i.e. PV, ET and PMF. To explain
this puzzle of ‘one-mutation-different diseases’,
different hypotheses have been advocated, alone
or in combination: (i) a different stem cell as the
target of the mutation; (ii) variable levels of JAK2
kinase activity as a reflection of the relative
proportion of mutated and wild-type protein in
the cell (‘mutational load theory’); (iii) the
specific genetic background of the host; (iv) a
pre-JAK2 molecular event; (v) a contributing
nonmutational factor, such as epigenetic mecha-
nisms [Vannucchi et al. 2009a], miRNA expres-
sion abnormalities [Guglielmelli, 2008], and
possibly others.
Indeed, it was soon recognized that the
JAK2V617F mutation, although integral to the
myeloproliferative process in murine models
(as described in the following), may not be the
sole molecular event in the human diseases. The
main factor supporting this theory initially came
from the discovery of mutations in TET2, a puta-
tive tumour suppressor gene located at 4q24, by
the group headed by William Vainchencker in
Paris [Delhommeau et al. 2009]. It was found
that TET2 mutations were contained in a
pre-JAK2 mutated cell through studies at the
single precursor cell level. However, subsequent
studies demonstrated a very complex mutational
pattern in most patients with MPNs, leading to
an appreciation of the mutational genetic
complexity of these disorders [Kralovics, 2008].
Other mutations beyond TET2 that can accom-
pany, precede, or follow JAK2V617F mutation
[Tefferi, 2010] have been reported in ASXL1
[Carbuccia et al. 2009], CBL [Grand et al.
2009], IDH1/IDH2 [Green and Beer, 2010;
Tefferi et al. 2010], EZH2 [Ernst et al. 2010]
and IKZF1/Ikaros [Jager et al. 2010]. These
mutations can be variably present during the
chronic or blastic phase of MPNs [Abdel-
Wahab et al. 2010; Tefferi, 2010].
The fact that almost 40% of ETor PMF patients
lack a molecular marker is a strong support to the
theory that mutations other than JAK2V617F
are involved in the pathogenesis, and possibly
affect the phenotype, of MPNs. In females with
JAK2V617F-positive ET, a clone of haemato-
poietic cells larger than that harbouring the
JAK2V617F mutation can exist, as shown by
results of analysis of X-chromosome inactivation
pattern (X-CIP) [Levine et al. 2006; Antonioli
et al. 2005]. In addition, in several
JAK2V617F-mutated patients with a del(20q),
the size of del(20)q and JAK2V617F-mutated
clones was different, suggesting that the V617F
allele had been acquired on the background of a
pre-existing del(20q) clone [Kralovics et al.
2006]. It is also of interest that the occurrence
of independently acquired biallelic JAK2 muta-
tions has been described [Olcaydu et al. 2009];
however, a recent reappraisal in ET patients,
using different techniques simultaneously, indi-
cated that in contrast to previous reports
[Lambert et al. 2009], the phenomenon is quite
rare [Beer et al. 2010b]. Some patients contem-
porarily harbour the JAK2V617F and
MPLW515L/K mutation [Guglielmelli et al.
2007; Pardanani et al. 2006], and clonal domi-
nance by the MPL mutated cells has been
demonstrated at least in some instances [Lasho
et al. 2006]. While seminal studies have shown
that the V617F allele is tightly associated with
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the growth of erythropoietin-independent
erythroid colonies (EECs), some EECs that
were wild-type for JAK2 have been detected at
low frequency in PV patients [Nussenzveig et al.
2007]. Finally, a variable proportion according to
the different studies [Rinaldi et al. 2010;
Theocharides et al. 2007] of blast cells of the
AML that developed in patients with a preceding
JAK2V617F-positive MPN have been found to
be JAK2V617F-negative. However, the pattern
of evolution of a MPN towards the leukaemic
phase may differ depending on the characteristics
of the chronic phase disease [Beer et al. 2010a].
The most likely explanation for the phenomenon
of these JAK2 wild-type blasts is that they derived
from the transformation of a pre-JAK2V617F
mutated haematopoietic stem cell that originally
expanded during the chronic phase of the MPN
after having acquired the V617F allele [Campbell
et al. 2006a].
On the other hand, at present there is little
evidence that differences in clinical phenotype
in patients harbouring the JAK2V617F mutation
originate from a different stem/progenitor cell
targeted by the mutational event. The V617F
allele has been found in myelolymphoid progen-
itors in patients with PV or PMF, as well as in
flow cytometry purified populations of haemato-
poietic stem cells and committed progenitors
[Delhommeau et al. 2007]. Similar observations
have been reported for the MPLW515L/K muta-
tion [Chaligne et al. 2007]. In only a minority of
ET cases has a restriction of V617F allele to
megakaryocytic lineage been described, although
it is unclear whether a very low burden of
mutated granulocytes might have escaped detec-
tion of the abnormal genotype [Bellosillo et al.
2007].
It is also likely that individual-related character-
istics contribute to the phenotypic pleiotropy of
the MPN [Vannucchi and Guglielmelli, 2008], as
originally hypothesized by results obtained in
animal models. In fact, in mice transplanted
with JAK2V617F mutated cells the characteris-
tics of the myeloproliferative disease they devel-
oped were dependent on their genetic
background; as a matter of fact the
JAK2V617F allele induced marked leukocytosis
and extensive marrow reticulin fibrosis in Balb/c
mice, in addition to erythrocytosis, in contrast to
C56Bl/6 mice that had a milder disease and no
leukocytosis, although they developed erythrocy-
tosis at comparable extent [Wernig et al. 2006].
Gender is another genetic-based host modifier
that may have relevance [Spivak, 2002], as well
as the body availability of iron stores. It was by
taking into an account these individual variables
that the hypothesis of a ‘biological continuum’ of
JAK2V617F mutated ET and PV was formu-
lated [Campbell et al. 2005].
Pathophysiology correlates of the JAK2V617F
allele burden
The possibility that the burden of JAK2mutation
has an influence on disease phenotype through
the level of activation of downstream JAK/
STAT signalling pathways is supported by several
experimental and clinical observations. First,
there are substantial differences in the median
burden of V617F allele in peripheral blood gran-
ulocytes among individual MPNs; the highest
levels are found in PV and the lowest in ET
patients [Vannucchi et al. 2008b; Passamonti
et al. 2006], with most PMF patients displaying
intermediatehigh levels. Most patients with
MPN-MF have high levels of the JAK2V617F
allele. Furthermore, homozygosity for the
JAK2V617F mutation, which follows mitotic
recombination of the short arm of chromosome
9 [Kralovics et al. 2002], is displayed by approx-
imately 30% of PV or PMF patients as opposite
to 24% of ET. Variable proportion of wild-type,
heterozygous and homozygous progenitors are
present in most patients with PV, while homozy-
gous progenitors are reported as being rare in ET
[Scott et al. 2006]. Erythroid progenitors
harbouring the V617F mutation are more sensi-
tive to erythropoietin than normal erythroid
progenitors, and most erythropoietin-indepen-
dent erythroid colonies are made up of homozy-
gous progenitors [Dupont et al. 2007].
Conceivably, duplication of the mutant allele is
expected to result in a level of JAK2/STAT acti-
vation higher than in cells harbouring one mutant
and one wild-type allele and in a greater activa-
tion of downstream genes [Vannucchi et al. 2006;
Kralovics et al. 2005b]. This could be due to the
loss of competition between normal and mutated
allele and/or impaired interaction of mutant
JAK2 with cellular regulators such as the
suppressor of cytokine signalling-3 (SOCS3)
[Hookham et al. 2007].
A correlation between mutant allele burden and
disease phenotype is indirectly supported also by
the phenotype developed by animals expressing
the JAK2V617F mutation. Retroviral vector
AM Vannucchi, L Pieri et al.
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models were characterized by the rapid appear-
ance of polycythemia, leukocytosis and spleno-
megaly, pointing to a PV-like disease that
eventually recapitulated the evolution to a post-
PV myelofibrosis [Lacout et al. 2006; Wernig
et al. 2006; Zaleskas et al. 2006]. The fact that
thrombocytosis was not observed in these mice
could have been due to the exceedingly high
levels of mutant JAK2 mRNA after the retroviral
infection. As a matter of fact, in transgenic mice
obtained with a conditional inverted allele of the
human JAK2V617F under the human JAK2
promoter, variable levels of JAK2V617F mRNA
versus the wild-type mRNA were obtained in
different founders [Tiedt et al. 2008]. In some
respects, the resulting phenotype closely reflected
the ratio between normal and mutated JAK2
mRNA. In fact, in mice expressing lower levels
of mutated JAK2 significant increases in leuko-
cytes, platelets and hemoglobin were detected;
the authors suggested that lower or higher
expression of JAK2V617F favours an ET or PV
phenotype, respectively [Tiedt et al. 2008].
Similar findings were reported by others [Shide
et al. 2008; Xing et al. 2008]. More recently,
three knock-in murine models were developed
through the introduction of the JAK2 mutation
into the host JAK2 locus to allow physiological
expression of the gene. In the two models that
used a mouse JAK2 for knocking in, a full
MPN phenotype developed with erythrocytosis,
thrombocytosis, splenomegaly and later evolu-
tion to myelofibrosis [Akada et al. 2010; Marty
et al. 2010]; the phenotype was more evident in
homozygous mice and correlated well with a
significantly higher level of JAK/STAT signalling
[Akada et al. 2010]. On the other hand, the group
of Tony Green developed a model of mice
expressing a conditional human JAK2V617F
allele; these mice presented a predominant
ET-like phenotype with thrombocytosis and
moderate erythrocytosis, but very little spleno-
megaly and no myelofibrosis [Li et al. 2010].
Of interest, these mice also presented an impair-
ment of stem cell function. As a whole, and by
taking into an account that these models cannot
reproduce the situation of human disease exactly
in terms of relative expression of mutated allele,
concomitant additional mutations, genetic back-
ground and balance between normal and
mutated stem cells, a general support to the
theory that expression level of the JAK2V617F
allele influences disease phenotype can certainly
be derived.
Clinical correlates of the JAK2V617F allele
burden in myeloproliferative neoplasms
Several studies, although not invariably and with
limitations due to their retrospective nature in
most cases, have shown that the V617F allele
burden correlates with haematologic characteris-
tics and clinical endpoints in MPN patients,
although it seems quite unlikely that the burden
of mutated allele represents the only mechanism
at the basis of MPN pleiotropy [Vannucchi et al.
2008b].
The largest study that compared JAK2V617F
heterozygous and homozygous PV and ET
subjects included 323 patients with PV (67.8%
heterozygous and 32.2% homozygous) and 639
patients with ET (40.2% wild type, 57.6%
heterozygous and 2.2% homozygous)
[Vannucchi et al. 2007b]. In both diseases,
homozygosity was associated with a stimulated
erythropoiesis and myelopoiesis, lower platelet
count, a higher incidence of splenomegaly,
larger spleen size, and a greater proportion of
patients requiring cytoreductive therapy.
Homozygous PV patients had also a higher inci-
dence of pruritus (42%). The rate of major
thrombosis was not increased in homozygous
patients with PV compared with heterozygous
patients, similar to the finding reported by
Tefferi and coworkers in a study that included
45 heterozygote and 13 homozygote PV patients
[Tefferi et al. 2006]. In contrast, thrombotic
events were definitively more frequent among
homozygous ET patients, with a hazard ratio
3.97-fold higher than in JAK2 wild type. The
association of homozygosity with cardiovascular
events in ET patients was maintained after
multivariate analysis, using as covariates other
established risk factors (age >60 years and previ-
ous history of thrombosis) [Finazzi and Barbui,
2005] as well as leukocytosis (white blood cell
counts greater than 8.7 109/L) [Carobbio
et al. 2007]. Furthermore, in both studies from
Vannucchi and colleagues and Tefferi and col-
leagues the number of PV patients who had a
fibrotic transformation was significantly higher
among homozygous than heterozygous groups
(23% vs. 2%, p¼ 0.009, in the Mayo study
[Tefferi et al. 2006] and 11.5% vs. 1.4%,
p< 0.001, in the Italian study [Vannucchi et al.
2007b]). Of note, the risk of having a fibrotic
transformation was significantly higher also
among homozygous ET patients (14.3% of
homozygous vs. 4.7% of heterozygous vs. 1.6%
of wild-type patients, p< 0.001) in the Italian
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study [Vannucchi et al. 2007c]. The relationships
between the burden of mutant allele and the
risk of developing myelofibrosis, that was main-
tained also on multivariable analysis, is
confirmed in a recent prospective series of
320 patients with PV; in contrast, the risk of
developing acute leukaemia was not significantly
related to mutant allele burden [Passamonti et al.
2010b]. As a whole, these data indicate that the
burden of JAK2V617F allele is associated with
the extent of myeloproliferation and with the
risk of evolution to myelofibrosis in both PV
and ET.
In a prospective study specifically addressing the
clinical significance of JAK2V617F homozygos-
ity, 173 patients with PV who were genotyped at
diagnosis were included. The main finding was
that a mutated allele burden greater than 75%
was associated with a 3.56-fold higher relative
risk (95% CI 1.477.1) of total thrombosis
[Vannucchi et al. 2007a]. Thus, patients with
PV who harbour the higher V617F allele
burden quartile may represent a subgroup at a
particularly higher risk of thrombosis. These
observations are supported by recently
published, retrospective series of 105 patients
with PV. A higher JAK2V617F allele burden
correlated with more advanced myelofibrosis,
greater splenomegaly and higher white blood
cell count [Silver et al. 2010]. Although a signif-
icant correlation with thrombosis risk could not
be defined, there was a trend towards increased
frequency of thrombosis as the JAK2V617F
allele burden increased. In contrast, in the
series of 320 PV patients published by
Passamonti and colleagues, no significant corre-
lation between V617F allele burden and throm-
bosis could be found [Passamonti et al. 2010b].
Finally, in a comparative retrospective study of
415 PV and 867 ET patients the frequency of
thrombosis was found to be progressively
increased in both diseases according to the
amount of JAK2V617F allele burden
[Carobbio et al. 2009]. The highest rate of
thrombosis was found among PV patients with
greater than 50% mutated allele. However, after
5 years from diagnosis the actuarial probability of
arterial and venous thrombosis was similar in PV
and JAK2V617F-mutated ET, and appeared to
be correlated with the progressively increasing
V617F allele burden over time. As a matter of
fact, 5 years after diagnosis the burden of
mutated allele represented the strongest and
unique risk factor associated with the rate of
subsequent thrombosis, while having a diagnosis
of PV or ET was not relevant [Carobbio et al.
2009]. In sum, further studies using rigorously
designed prospective analysis are necessary to
definitively ascertain the predictive role of a
high JAK2V617F allele burden for the risk of
thrombosis in PV. On the other hand, a
JAK2V617F-mutated status has a defined role
in thrombosis in ET, as shown in three indepen-
dent meta-analyses including more than 2000
patients, with a predicted overall risk of about
two. In a study of 260 ET patients, microvessel
symptoms were significantly more represented
among those with greater than 25% mutated
allele and there was a higher frequency of arterial
thromboses at diagnosis, confirmed also on
multivariate analysis, with a relative risk of 3.0
(95% CI 1.36.8; p¼0.01) [Antonioli et al.
2008].
Primary myelofibrosis is associated with poorer
prognosis compared to the other MPN; however,
since survival may range from a few months to an
excess of decade, the identification of variables
associated with prognosis is of considerable impor-
tance for driving therapeutic decisions. The
International Working Group for Myelofibrosis
Research and Treatment (IWG-MRT) developed
a new prognostic score system which is capable of
discriminated four categories of patients with sig-
nificantly different median survival in the range of
27 to 135 months [Cervantes et al. 2009]. A
dynamic International Prognostic Score System
(IPSS) has also been validated [Passamonti et al.
2010a]. This notwithstanding, the search for bio-
logical variables that could function as biomarkers
of disease activity and/or evolution is of outmost
relevance; some studies have evaluated the correla-
tion of JAK2V617F mutational status and V617F
mutated allele burden with disease outcome
in PMF.
In a series of 168 PMF patients a statistically
significant association of the JAK2V617F
mutated status with a more pronounced myelo-
proliferative phenotype was found [Guglielmelli
et al. 2009b], similar to findings reported by
Campbell and colleagues [Campbell et al.
2006b] and Barosi and colleagues [Barosi et al.
2007], but partially different from a Mayo Clinic
report [Tefferi et al. 2008, 2005]. In the above
study, JAK2V617F mutated patients were signif-
icantly less anaemic than wild type, but neither
overall survival nor leukaemia transformation
were different in the two categories of patients
AM Vannucchi, L Pieri et al.
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defined by their JAK2V617F genotype. These
results are in line with the study of Tefferi and
colleagues [Tefferi et al. 2008], but in disagree-
ment with the results of an English study
[Campbell et al. 2006b] that reported a hazard
ratio of shortened survival of 3.3 (95% CI
1.268.68) in patients harbouring the V617F
allele [Campbell et al. 2006b]. Therefore, it
seems unlikely that a JAK2V617F mutated
status per se reflect in a poorer prognosis in
PMF. By quantifying V617F allele burden in
PMF patients, Tefferi and colleagues [Tefferi
et al. 2008] first described a poorer survival in
patients harbouring low mutated allele burden.
These findings were confirmed by Guglielmelli
and colleagues [Guglielmelli et al. 2009b].
In the latter study it was found that patients
included in the lower quartile had significantly
shorter progression time to anaemia, leukopenia
and conversely longer time to large splenomegaly
compared with patients in the upper quartiles;
furthermore, patients in the lower quartile had
a significantly reduced overall survival compared
with both upper quartiles and JAK2 wild-type
patients. Reduced survival was mainly due to
leukaemic transformation in the Mayo Clinic
study [Tefferi et al. 2008] and to systemic infec-
tions in the Italian study [Guglielmelli et al.
2009b]. On the other hand, neither a mutated
JAK2V617F status nor the mutated allele
burden appeared to have clinical relevance in a
study of 65 patients with post-PV or PET-MF
[Guglielmelli et al. 2009a]. In summary, a low
JAK2V617F allele burden at diagnosis seems to
be a strong surrogate marker associated with
shortened survival in PMF, although the causes
of death as well as the pathobiological mecha-
nisms underlying this correlation remain to be
established fully.
In a collaborative study that retrospectively eval-
uated 707 patients with PMF for the rate and
predictive factors for major cardiovascular vascu-
lar, Barbui and coworkers [Barbui et al. 2010]
reported a 7.2% rate of fatal and nonfatal throm-
bosis. Variables associated with thrombosis in a
multivariable model were age greater than 60 and
a JAK2V617F mutated genotype, producing a
hazard ratio of 1.92 (95% CI 1.103.34,
p¼ 0.02). No information has yet been made
available in the literature about the significance
of V617F allele burden.
A JAK2V617F allele burden exceeding 50% was
found in about one quarter of prefibrotic PMF
(median value in the 102 patients, 38%) unlike in
ET where none of the 90 patients displayed an
allele burden greater than 40%, with a median
value of 24% [Hussein et al. 2009]. Therefore,
according to Hussein and colleagues, a
JAK2V617F allele burden greater than 50%
would favour a diagnosis of prefibrotic PMF
rather than ET [Hussein et al. 2009].
Utility of the JAK2V617F allele burden for
measuring response to treatment
The occurrence of a specific molecular abnor-
mality in a proportion of MPN patients ranging
from 60% to greater than 95% represents a
potentially useful biomarker for evaluating the
effects induced by different drugs on the mutated
clone. Before analyzing in more detail the small
amount of information that is currently available
regarding this, it is appropriate to take some
general considerations into account. First, there
are methods validated as yet for measuring the
burden of V617F allele, although several meth-
ods claiming to be sensitive and specific have
been published over the years, and a multicentre
evaluation of a number of those assays has been
accomplished recently [Lippert et al. 2008].
Second, the fact that the JAK2V617F mutation
can arise in clones harbouring other mutations,
potentially more relevant for the initiation of the
disease, means that reduction of the V617F allele
burden even up to its undetectability does not
necessarily signify remission or cure of the under-
lying MPN [Kiladjian et al. 2010].
The effects of hydroxyurea on the burden of
V617F allele have been addressed in a few studies
with different results. In a retrospective single-
centre study in 48 patients the V617F allele
burden was not apparently modified over time
in most of the patients who were already under
hydroxyurea at the time of blood sampling.
However, in five of six patients in whom hydroxy-
urea was started during the follow up, a statisti-
cally significant decrease of JAK2V617F allele
burden was reported after 6 months; halting the
treatment caused the level of mutant allele to
increase [Theocharides et al. 2008]. Hussein
and colleagues failed to observe changes in the
V617F allele burden after hydroxyurea treatment
[Hussein et al. 2009], while Girodon and
coworkers reported a significant reduction of
mutant allele in 36 patients with PV or ET from
a median of 43% at diagnosis to 24% at
15 months after starting hydroxyurea [Girodon
et al. 2008]. In three ET patients the mutation
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was no longer detectable after 555 months of
treatment. Of interest, in both PV and ET,
changes in V617F allele burden produced by
hydroxyurea treatment were more prominent in
women than in males. A significant decrease of
JAK2V617F burden has been also documented
in 72% of 18 patients (9 PV and 9 ET) consid-
ered by Ricksten and colleagues after only
4 months of therapy with hydroxyurea [Ricksten
et al. 2008]. In a study conducted in two Italian
institutions that included 172 patients, a minimal
(less than 10%), reduction of V617F allele
burden was observed only in the group of newly
treated ET patients, in accordance with a previ-
ous study [Theocharides et al. 2008]. A reduction
of V617F allele burden consistent with the defi-
nition of ‘partial response’ according to the
European LeukemiaNet (ELN) criteria [Barosi
et al. 2009] involved 15% of ET patients and
12% of PV patients. In summary, the bulk of
current evidence seems to suggest that hydroxy-
urea can produce some reduction in the
JAK2V617F allele burden in subsets of patients
[Girodon et al. 2008; Ricksten et al. 2008;
Theocharides et al. 2008], but the clinical rele-
vance of this observation is questionable. On the
other hand, it is clinically relevant that patients
with PMF who harboured the JAK2V617F
mutation were more sensitive to hydroxyurea
than the wild-type counterpart on multivariable
analysis and that in PV the JAK2V617F allele
burden correlated directly with the response to
drug and inversely with the daily dose in respond-
ing patients [Sirhan et al. 2008].
Kiladjian and colleagues reported a significant
reduction in the V617F allele burden, including
some documented cases of apparent molecular
remission, in a trial that included 37 evaluable
patients with PV treated with pegylated inter-
feron alpha 2a. [Kiladjian et al. 2008]. In a
similar study performed at the MD Anderson
Cancer Center in 79 patients, both PV and ET,
the molecular response rate was lower than in
the French study, with 54% overall response
but only 14% of the PV patients having undetect-
able V617F [Quintas-Cardama et al. 2009].
In contrast, modest if any changes in V617F
allele burden have been reported by the group
of Silver, who pioneered the use of interferon in
PV [Jones et al. 2006]. Very important, the
changes in the JAK2V617F allele burden did
not mirror the effect of the drug on the frequency
of TET2 mutated haematopoietic progenitors
[Kiladjian et al. 2010].
The identification of autonomously activated
JAK/STAT signalling in MPNs has guided the
clinical development of small molecules acting
as JAK2 inhibitors [Verstovsek, 2010;
Pardanani, 2008]. The first trial with one of
these inhibitors, INCB018424, in myelofibrosis
has been published recently [Verstovsek et al.
2010]; furthermore, a multicentre phase II
study in advanced, hydroxyurea-resistant PV or
ET has completed enrolment. CEP701, or
Lestaurtinib, and TG101348 are also undergoing
clinical evaluation [Verstovsek, 2010; Pardanani,
2008]. It is a little disappointing that the appre-
ciable results of INCB018424 in terms of clinical
improvement were not mirrored by a significant
reduction of the JAK2V617F allele burden,
pointing to mechanisms other than simple reduc-
tion of mutated clonal progenitors load to explain
the clinical benefits of the drug [Vannucchi,
2010]. Evidence of a trend towards reduction of
the V617F allele burden has been reported in a
phase II study in PMF patients treated with
Givinostat [Rambaldi et al. 2010], a novel orally
available histone deacetylases inhibitor that
in vitro caused significant inhibition of V617F
mutated cells through the downregulation of
JAK2 mRNA levels [Guerini et al. 2008].
In the setting of allogeneic stem cell transplanta-
tion for myelofibrosis the quantification of
V617F allele burden may have a clinical impact
for posttransplant therapeutical strategies, in
particular for guiding adoptive immunotherapy
[Kroger et al. 2009a; Benjamini et al. 2008].
In a study performed by Kroger and colleagues,
78% of 21 patients became PCR negative for the
JAK2V617F mutation at a median of 89 days
after allograft [Kroger et al. 2009b].
JAK2V617F negativity correlated well with the
donor-cell chimerism. In one case, residual
JAK2-positive cells could be successfully elimi-
nated by donor lymphocyte infusion. In another
study, 139 myelofibrosis patients who received a
reduced-intensity regimen in preparation to
transplantation were considered [Alchalby et al.
2010]. It was found that JAK2 wild-type patients
had significantly reduced overall survival on
multivariate analysis (HR 2.14, p¼ 0.01) in
comparison to JAK2 mutated patients, while
the V617F mutated allele burden, analyzed
either as continuous variable or after dividing in
quartiles, had no impact on the outcome.
Furthermore, patients who cleared JAK2 muta-
tion level in peripheral blood at 6 months after
AM Vannucchi, L Pieri et al.
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transplant had a significant lower risk of relapse
(5% vs. 35%).
Conclusions
The discovery of the JAK2V617F mutation and
its association with distinct haematological and
clinical characteristics has prompted studies
aimed at assessing the predictive value of muta-
tional status and of the burden of V617F allele
for the most common complications of PVor ET,
i.e. vascular events, for transformation to myelo-
fibrosis or acute leukaemia, and more in general
for prognosis and survival, especially survival in
PMF. Although most of studies were retrospec-
tive in nature, the methods for genotyping and
the source of cells were used for genotyping
different, and notwithstanding the findings were
sometimes conflicting, there is enough evidence
to suggest that the burden of mutated allele
correlates with defined aspects of the phenotype
of MPN and major clinical endpoints. Therefore,
these correlative studies support the contention
that quantification of JAK2V617F allele burden
might convey relevant clinical information in
well-defined categories of MPN patients.
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